Is CorMedix Inc. (NASDAQ:CRMD) a buy in 2026?
Yes, on balance. The Compass leans toward accumulating CorMedix Inc. at current levels.
DefenCath's hospital ramp is real, the dialysis chain conversion is happening, and the market is treating a profitable rare-disease story like a binary biotech.
Where CRMD is headed
CorMedix walks into 2027 as something the buy-side rarely gets to own: a single-product specialty pharma generating $120M+ in free cash flow, growing the top line triple digits off a base most analysts still model as a niche dialysis play. DefenCath has moved past the 'will the big dialysis chains adopt it' question. US Renal Care is on a multi-year contract, and the conversation has shifted to penetration depth inside DaVita and Fresenius rather than whether they take the drug at all. At a 91.9% gross margin and 50% operating margin on a single SKU, every incremental patient flows straight to the bottom line, and management is sitting on a balance sheet that gives them runway to push label expansion into TPN (total parenteral nutrition) and pediatric populations without dilution.
Read the full Compass Direction on CRMD
The complete destination call, the overlooked angle, milestones, and bull, base, and bear price scenarios (around $8.66).
See the full CRMD analysisGet calls like this, free
Join the Alexandria e-letter for forward-looking verdicts, earnings intelligence, and the contrarian reads the crowd misses. Twice a week, no noise.
Free forever. Unsubscribe anytime. We never share your email.
Frequently asked questions
Is CorMedix Inc. (NASDAQ:CRMD) a buy in 2026?
Yes, on balance. The Compass leans toward accumulating CorMedix Inc. at current levels. DefenCath's hospital ramp is real, the dialysis chain conversion is happening, and the market is treating a profitable rare-disease story like a binary biotech.
What is CRMD's Compass Score?
CorMedix Inc. scores 82/100 on Alexandria's Compass, placing it in the "True North" tier. Scores blend eight factors and update weekly.
What is the price target for CRMD?
Alexandria's full Compass Direction includes bull, base, and bear price scenarios with the valuation math behind each. Read the full breakdown on the CRMD page.
Compass verdicts are AI-generated, forward-looking editorial research from publicly available data, not investment advice or a recommendation regarding any security. Scores and verdicts update as the data changes.